Ingenane diterpenoids, LDL uptake, PCSK9, LDLR
Immunotherapy, IL-15, immunocytokine, dose-limiting toxicities, prodrug, immune checkpoint inhibitors, resistance
CMTM6, PD-L1, CMTM6-PD-L1 complex, membrane mimetic, nanobody